Cloudbreak Pharma Announces Successful End-of-Phase-2 Meeting and Alignment with FDA on Phase 3 Path Forward for CBT-004
CBT-004, if approved, would be the first and only treatment for pinguecula, an ophthalmic condition impacting more than 50 million...